T cell responses to SARS-CoV-2 vaccination differ by disease-modifying therapy for multiple sclerosis
Description
Immune responses in people with multiple sclerosis (pwMS) on disease-modifying therapies (DMTs) have been of significant interest throughout the COVID-19 pandemic. Lymphocyte-targeting immunotherapies including anti-CD20 treatments and sphingosine-1